Eric Lechtzin is a shareholder in the firm’s Securities, Consumer Protection, ERISA and Employment & Unpaid Wages Litigation practice groups.
Mr. Lechtzin has been instrumental in helping Berger & Montague, P.C. secure leadership positions and obtain settlements in national securities fraud class actions, including In re: Oppenheimer Rochester Funds Group Securities Litigation, No. 09-md-02063-JLK (D. Col.) ($89.5 million settlement); In re Hemispherx Biopharma, Inc. Litigation, 09-cv-5262-PD (E.D. Pa. 2010) ($3.6 million settlement); Beckman Coulter, Inc. Securities Litigation, No. 8:10-cv-1327 (C.D. Cal. 2011) ($5.5 million settlement).
Among his successful representations in the area of consumer fraud is Silver v. Fitness Intern., LLC, No. 10-cv-2326-MMB, 2013 WL 5429293 (E.D. Pa. ), a class action against a national health club chain that resulted in substantial changes of its cancellation policies and practices.
Mr. Lechtzin is the Pennsylvania State Chair for the National Association of Consumer Advocates. He has been named a “Super Lawyer” in Pennsylvania for Class and Mass Tort Litigation, and is AV Preeminent rated by Martindale Hubble.
- “Attorney Fees in Class Action Settlements,” Panelist, National Association of Legal Fee Analysis, August 24, 2017
- “Expert Testimony & Daubert Motions,” Presenter, 2016 Consumer Rights Litigation Conference
- “Settlement Tenders After Campbell-Ewald v. Gomez,” Presenter, 16th Annual Consumer Class Action Symposium, 2016
- “Trends in Foreclosure-Related Class Actions,” Presenter, NLADA Litigation Directors Conference, 2014
Pennsylvania State Chair, National Association of Consumer Advocates, 2017-present
Appointed by Chancellor of the Philadelphia Bar Association to the Investigative Division of Commission on Judicial Selection & Retention (2002 to 2003)
Member, National Association of Consumer Advocates, 2016-present
Member, American Bar Association
Member, Philadelphia Bar Association
Prominent Judgments and Settlements
- In re Oppenheimer Rochester Funds Group Securities Litigation, No. 09-md-02063-JLK (D. Col.) ($89.5 million).
- In re Hemispherx Biopharma, Inc. Litigation, 09-CV-5262-PD (E.D. Pa. April 19, 2010) (alleged § 10(b) violations upheld against the pharmaceutical company)
- Matt Brody v. Zix Corp., 2006 U.S. Dist. LEXIS 69302 (N.D. Tex. Sept. 26, 2006) (defeated defendants’ motion to dismiss)
- In re LaBranche Sec. Litig., 405 F. Supp. 2d 333 (S.D.N.Y. 2005) (alleged § 10(b) violations upheld against NYSE specialist firm accused of manipulative trading)
- In re Transkaryotic Therapies, Inc. Sec. Litig., No. 03-CV-10165-RWZ (D. Mass.) (defeated motion to dismiss and won class certification motion; ultimately settled for $50 million)
- In re Global Crossing Access Charge Litigation, No. 04-MD-1630 (S.D.N.Y) ($15 million settlement – more than a third of the damages sustained by the class)
- Taft v. Ackermans, (KPNQwest Securities Litigation), No. 02-CV-7951 (S.D.N.Y.) ($15 million settlement)
- In re Renaissance Holdings Ltd. Securities Litigation, No. 1:05-CV-6764 (S.D.N.Y.) ($13.5 million settlement)
- In re Van der Moolen Holding N.V. Securities Litigation, No. 1:03-CV-8284 (S.D.N.Y.) (defeated defendants’ motion to dismiss and secured an $8 million settlement – more than a third of the damages sustained by the class)
- Scott Tanne v. Autobytel, Inc., et al, No. CV 04-8987 (C.D. Cal.) ($6.75 million settlement)
- In re Biolase Technology, Inc. Securities Litigation, No. 8:04-CV-947 (C.D. Cal. July 25, 2006) (defeated motion to dismiss claims alleging violations of § 11 of the Securities Act of 1933; $2.95 million settlement)
- In re TV Azteca S.A. de C.V. Securities Litigation, 04-cv-00546-JES (S.D.N.Y.) (obtained a settlement that, when combined with SEC Fair Funds, represented a recovery of nearly 100% damages sustained by the class)